BRIEF—Ferrer to promote Rizmoic in Spain

Japan’s Shionogi and privately-held Spanish drugmaker Ferrer concluded an exclusive promotion agreement for Rizmoic (naldemedine) in Spain for the treatment of opioid-induced constipation (OIC) in adult patients previously treated with a laxative.

Shionogi has built a strong heritage in research-based medicine and the company’s R&D efforts target pain/central nervous system as one of its priority therapeutic areas of interest.

Ferrer’s activity covers the entire health spectrum in Spain and many other countries worldwide, including expertise in pain management by opioid treatment.

This collaboration marks an additional key milestone for the launch of Rizmoic in Europe.

On February 18, 2019, the European Commission granted the Marketing Authorization for Rizmoic for the treatment of OIC in adult patients who have previously been treated with a laxative.

Rizmoic is planned to be launched in Spain in 2020.

Rizmoic was launched under the brand name Symproic in Japan in June 2017, and in the USA in October 2017.